Publication details

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer

Authors	SKŘIČKOVÁ Jana PESEK M OPALKA P KOUBKOVA L ZEMANOVA M HRNCIARIK M BLAZEK J SVATON M KREJCI J COUPKOVA H DOLEZAL D TUZOVA T HOLUBEC L MAHADEVIA P SANDSTROM K KUNOVSZKI P BARINOVA M HURDALKOVA K FISCHER O CERNOVSKA M BRATOVA M
Year of publication	2021
Type	Article in Periodical
Magazine / Source	Anticancer Research
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.21873/anticanres.15378
Keywords	EGFR exon-20 insertions; NSCLC; prognostic values; RWE
Description	Background/Aim: Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations. Patients and Methods: We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020. Results: We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions. Conclusion: Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.